Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye injection aims to tame leading causes of blindness

NCT ID NCT04516278

Completed Disease control Sponsor: Outlook Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests the safety of an experimental eye injection called ONS-5010 (bevacizumab) in people with vision loss from wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. Participants receive the injection and are monitored for side effects over three months. The goal is to see if this treatment is safe enough to move forward as a potential therapy for these common retinal conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bevacizumab (also called ONS-5010), given as an injection into the eye
What this could lead to
If successful, this could provide a safe, approved option for treating common causes of vision loss like wet AMD and diabetic macular edema.
What could go wrong
This is a safety-focused trial, so it won't prove how well the drug works. Side effects from eye injections, such as infection or inflammation, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration branch retinal artery occlusion diabetic macular edema macular degeneration occlusion of tributary of retinal vein retinal vein occlusion wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION BRVO - BRANCH RETINAL VEIN OCCLUSION DIABETIC MACULAR EDEMA NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WET MACULAR DEGENERATION

Contacts and locations

Locations

  • Clinical Site

    Tucson, Arizona, 85710, United States

  • Clinical Site

    Beverly Hills, California, 90211, United States

  • Clinical Site

    Glendale, California, 91203, United States

  • Clinical Site

    Long Beach, California, 90807, United States

  • Clinical Site

    Palm Desert, California, 92260, United States

  • Clinical Site

    Poway, California, 92064, United States

  • Clinical Site

    Clearwater, Florida, 33761, United States

  • Clinical Site

    Winter Haven, Florida, 33880, United States

  • Clinical Site

    Oak Forest, Illinois, 60452, United States

  • Clinical Site

    Springfield, Illinois, 62704, United States

  • Clinical Site

    Hagerstown, Maryland, 21740, United States

  • Clinical Site

    Albuquerque, New Mexico, 87109, United States

  • Clinical Site

    Chambersburg, Pennsylvania, 17201, United States

  • Clinical Site

    Rapid City, South Dakota, 57701, United States

  • Clinical Site

    Germantown, Tennessee, 38138, United States

  • Clinical Site

    Abilene, Texas, 79606, United States

  • Clinical Site

    Arlington, Texas, 76012, United States

  • Clinical Site

    McAllen, Texas, 78503, United States

  • Clinical Site

    San Antonio, Texas, 78251, United States

  • Clinical Site

    Willow Park, Texas, 76087, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.